F097 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Still a Bunch of Management Controversies
DESCRIPTION
In the management of Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) there is a consensus concerning only the supportive care, topical and systemic therapies are still subject of controversies. In the first part will be presented the efficacy and tolerance of etanercept associated with topical silver Nitrate in spray in SJS. In the second part will be presented published data and controversies in the management of SJS/TEN. Based on the literature review and on our experience, we propose a management algorithm for SJS/TEN.
LEARNING OBJECTIVES
Describe the main clinical features, etiology and on controversies in management options of Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
Discuss the results of subcutaneous etanercept single dose associated with silver nitrate 0.5% spray in SJS. Compare this treatment with other treatments for SJS/TEN
Differentiate between different management options in SJS and TEN.
SCHEDULE
3:30 PM
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Still a Bunch of Management Controversies.
Marius Anton Ionescu, MD, PhD, IFAAD
3:45 PM
SJS/TEN: Best Supportive Care Above All.
Saskia Oro
4:05 PM
Etanercept and Topical Silver Nitrate in SJS and TEN.
Jose Dario Martinez, MD, IFAAD
4:25 PM
Systemic Treatments for SJS and TEN - the Case For - and Against.
Mark D.P. Davis, MD, FAAD
4:45 PM
IVIG for Treatment of SJS/TEN: Current Evidence.
Anthony Fernandez, MD, FAAD
5:05 PM
Beyond SJS/TEN: High Stakes Mimics in Oncology Patients
Cuong Nguyen, MD, FAAD
5:25 PM
Questions and Answers
DIRECTOR
Marius Anton Ionescu, MD, PhD, IFAAD
SPEAKERS
Mark D.P. Davis, MD, FAAD
Anthony Fernandez, MD, FAAD
Jose Dario Martinez, MD, IFAAD
Cuong Nguyen, MD, FAAD
Saskia Oro
DISCLOSURES
Mark D.P. Davis, MD, FAAD
No financial relationships exist with ineligible companies.
Anthony Fernandez, MD, FAAD
AbbVie – Consultant(Honoraria), Speaker(Honoraria); Astra Zeneca – Investigator(Grants/Research Funding); AstraZeneca – Investigator(Grants/Research Funding); Biogen – Consultant(Honoraria); BMS – Speaker(Honoraria); Boehringer Ingelheim – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Investigator(Grants/Research Funding); EMD Serono – Consultant (1099 relationship)(Honoraria); Galderma – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Investigator(Grants/Research Funding); Kyowa Kirin – Speaker(Honoraria); Mallinckrodt Pharmaceuticals – Investigator(Grants/Research Funding), Speaker(Honoraria); Novartis Pharmaceuticals Corp. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); UCB – Consultant(Honoraria);
Marius Anton Ionescu, MD, PhD, IFAAD
AbbVie – Speaker(Honoraria); BMS – Speaker(Honoraria); Celgene Corporation – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Speaker(No Compensation Received); Laboratoire Dermatologiques d'Uriage – Advisory Board(Honoraria); Novartis – Speaker(Honoraria); UCB – Speaker(Honoraria);
Jose Dario Martinez, MD, IFAAD
No financial relationships exist with ineligible companies.
Cuong Nguyen, MD, FAAD
No financial relationships exist with ineligible companies.